(Open access funding provided by Semmelweis University)
(TKP2021-EGA-08)
(IV/365–2/2022/EKF)
Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009)
Támogató: EFOP-VEKOP
NTP-NFTÖ-21-B(Nemzet Fiatal Tehetségeiért Ösztöndíj 2021) Támogató: Emberi Erőforrások
Minisztériuma
(UNKP-19-3-I-SE-74)
Convalescent plasma therapy might be a feasible option for treatment of novel infections.
During the early phases of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
pandemic, several promising results were published with convalescent plasma therapy,
followed by more disappointing findings of randomised controlled trials. In our single-centre,
open-label, prospective, cohort study, we assessed the findings of 180 patients treated
with convalescent plasma during the first four waves of the pandemic in Hungary. The
primary outcome was all-cause mortality; secondary outcomes were clinical improvement
and need for intensive care unit admission by day 28. Subgroup analysis comparing
elderly and non-elderly (less than 65 years of age) was performed. Twenty (11.4%)
patients died by day 28, at significantly higher rates in the elderly subgroup (3
vs. 17, p < 0.01). One hundred twenty-eight (72.7%) patients showed clinical improvement,
and 15 (8.5%) were transferred to the intensive care unit until day 28. Non-elderly
patients showed clinical improvement by day 28 in significantly higher rates (improvement
74 vs. 54, no improvement 15 vs. 11, worsening or death 4 vs. 18 patients, p < 0.01).
In conclusion, we found similar clinical outcome results as randomised controlled
trials, and the impact of risk factors for unfavourable clinical outcomes among patients
in the elderly population.
